Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort.
about
Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis.Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice.Comorbidities in Spondyloarthritis.
P2860
Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@en
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@nl
type
label
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@en
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@nl
prefLabel
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@en
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@nl
P2093
P2860
P356
P1433
P1476
Tumour necrosis factor inhibit ...... itudinal observational cohort.
@en
P2093
Arane Thavaneswaran
Dinny Wallis
Renise Ayearst
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEU255
P577
2014-08-13T00:00:00Z